6.2 CEE MYELOMA TRIAL ANALYTICS: RESULT DETAILS

6.2.1. LIST OF CEE MYELOMA RESEARCH CENTRES/HOSPITALS BETWEEN 1 JANUARY 2001 AND 28 SEPTEMBER 2020

Table 5: Identified CEE myeloma research centres

Country	Identified myeloma research centres
Czech Republic	9
Poland	21
Russian Federation	19
Hungary	9
Ukraine	20
Bulgaria	4
Romania	5
Lithuania	1
Serbia	4
Slovakia	2
Croatia	3
Estonia	1
Belarus	1
TOTAL	**100**

Table 6: Czech Republic's myeloma research centres

	Myeloma research centres
1	Fakultní nemocnice Královské Vinohrady. Praha 10, Praha, Czechia
2	Fakultní nemocnice Olomouc. Olomouc, Severomoravsky KRAJ, Czechia
3	FN Ostrava. Ostrava, Severomoravsky KRAJ, Czechia
4	Fakultní nemocnice Hradec Králové, Hradec Kralové, Vychodocesky KRAJ, Czechia
5	Fakultní nemocnice Brno. Brno, Czechia
6	Všeobecná fakultní nemocnice v Praze. Praha, Czechia
7	Fakultni nemocnice Hradec Kralove. Hradec Kralove, Kralovehradeck Kraj, Czechia, 500 05
8	Vseobecna fakultni nemocnice v Praze. raha 2, Czechia, 128 08
9	University Hospital Ostrava. Ostrava, Czechia

APPENDICES

Table 7: Poland's myeloma research centres

	Myeloma research centres
1	Medical University of Gdansk. Gdansk, Poland, 80-211 Contact: Andrzej W. Hellmann, MD, PhD 48- 58-349-2230
2	Silesian Medical Academy. Katowice, Poland, 40-029 Contact: Jerzy Holowiecki, MD, PhD 48-32-256-2858 holow@slam.katowice.pl
3	Institute of Haematology and Blood Transfusion. Warsaw, Poland, 00-957 Contact: Krzysztof Warzocha, MD, PhD 48-22-849-8507 warzocha@ihit.waw.pl
4	Specjalistyczny Szpital Miejski im. Mikolaja Kopernika. Torun, Kujawsko-Pomorskie, Poland
5	Zamojski Szpital Niepubliczny Sp. z o.o. Zamosc, Lubelskie, Poland
6	Szpital Uniwersytecki w Krakowie. Krakow, Malopolskie, Poland
7	Instytut Hematologii i Transfuzjologii. Warszawa, Mazowieckie, Poland
8	Uniwersyteckie Centrum Kliniczne. Gdansk, Pomorskie, Poland
9	Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespól Szpitali Miejskich. Chorzów, Slaskie, Poland
10	Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im K. Marcinkowskiego w Poznaniu. Poznan, Wielkopolskie, Poland
11	MTZ Clinical Research Sp z o o. Warszawa, Mazowieckie, Poland, 02-106
12	Szpital Uniwersytecki Nr 2 im. Dr Jana Biziela w Bydgoszczy. Bydgoszcz, Poland, 85-168
13	Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wroclawiu. Wroclaw, Poland, 50-367
14	Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im. Ks. B. Markiewicza. Brzozow, Poland, 36-200
15	Szpitale Pomorskie Sp. z o.o. Gdynia, Poland, 81-519
16	Wojewodzki Szpital Specjalistyczny w Legnicy. Legnica, Poland, 59-220
17	Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie. Lublin, Poland, 20-081
18	Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy. Warszawa, Poland, 02-781
19	Uniwersytet Jagiellonski Collegium Medicum. Kraków, Poland
20	Akademia Medyczna w Gdansku Katedra i Klinika Hematologii i Transplantologii. Gdansk, Poland, 80-211
21	Polish Myeloma Consortium. Szamarzewskiego 84, Poznan, Poland, 60-569 info@pmc.edu.pl

APPENDICES

Table 8: Russian Federation's myeloma research centres

	Myeloma research centres
1	Republican Clinical Hospital #1. Izhevsk, Russian Federation
2	City Clinical Hospital n.a. S. P. Botkin. Moscow, Russian Federation
3	Non-state Healthcare Institution "N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway. Moscow, Russian Federation
4	Ryazan Regional Clinical Hospital. Ryazan, Russian Federation
5	Clinical Hospital Number 31. Saint Petersburg, Russian Federation
6	Federal Almazov Medical Research Centre. Saint Petersburg, Russian Federation
7	FGU Russian Scientific Research Institute of Hematology and Transfusiology. Saint Petersburg, Russian Federation
8	First Saint Petersburg I.P. Pavlov State Medical University. Saint Petersburg, Russian Federation
9	GUZ Samara Regional Clinical Hospital n.a. M.I. Kalinin. Samara, Russian Federation
10	State Medical and Preventive Treatment Institution Kirov Regional Clinical Oncology Dispensary. Kirov, Russian Federation, 610027
11	Stavropol Regional Clinical Oncology Centre Pyatigorsk Affiliate. Pyatigorsk, Russian Federation, 357500
12	Russian Research Institute of Hematology and Blood Transfusion. St. Petersburg, Russian Federation, 193024
13	Emergency Hospital of Dzerzhinsk. Dzerzhinsk, Russian Federation, 606019
14	Ekaterinburg City Clinical Hospital # 7. Ekaterinburg, Russian Federation, 620137
15	City Clinical Hospital # 40. Moscow, Russian Federation, 129301
16	Nizhniy Novgorod Region Clinical Hospital. Nizny Novgorod, Russian Federation, 603126
17	Penza Regional Oncology Dispensary. Penza, Russian Federation, 440071
18	Samara Region Clinical Hospital. Samara, Russian Federation, 443095
19	Oncology Dispensary of Komi Republic. Syktyvkar, Russian Federation, 167904

Table 9: Hungary's myeloma research centres

	Myeloma research centres
1	Bács-Kiskun Megyei Kórház Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza. Kecskemét, Bacs-kiskun, Hungary
2	Pécsi Tudományegyetem. Pécs, Baranya, Hungary
3	Szegedi Tudományegyetem. Szeged, Csongrad, Hungary
4	Debreceni Egyetem Klinikai Központ. Debrecen, Hajdu-bihar, Hungary
5	Egyesített Szent István és Szent László Kórház-Rendelointézet. Budapest, Hungary
6	Somogy Megyei Kaposi Mac okato Korhoz. Kaposvár, Hungary
7	Somogy Megyei Kaposi Mór Oktató Kórház. Kaposvár, Hungary
8	Semmelweis Egyetem. Budapest, Hungary, 1083
9	Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont. Szeged, Hungary, 6725

APPENDICES

Table 10: Ukraine's myeloma research centres

	Myeloma research centres
1	City Hematology Center. Dnepropetrovsk, Dnipropretrovsk, Ukraine
2	Municipal Institution of Health Protection "Clinical Hospital #8". Kharkov, Kharkiv, Ukraine
3	Cherkassy Regional Oncology Center. Cherkassy, Ukraine
4	MI "Dnipropetrovsk City Multifield Clinical Hospital #4" of Dnipropetrovsk Regional Council", City Hematology Center. Dnipropetrovsk, Ukraine
5	Institute of Urgent and Reparative Surgery of Ukraine Academy of Medical Sciences. Donetsk, Ukraine
6	Khmelnytsky Regional Clinical Hospital. Khmelnytsky, Ukraine
7	Khmelnytsky Regional Hospital, Department of Hematology. Khmelnytsky, Ukraine
8	National Institute of Cancer, Oncohematology Department. Kiev, Ukraine
9	Kyiv Bone Marrow Transplantation Center. Kyiv, Ukraine
10	Lviv Regional Oncology Dispensary. Lviv, Ukraine
11	Lviv State Oncology Regional Treatment-Prophylactic Center, Department of Chemotherapy. Lviv, Ukraine
12	Regional Clinical Hospital. Mykolayiv, Ukraine
13	Communal Nonprofit Enterprise 'Cherkasy Regional Oncology Dispensary Of Cherkasy Regional Council. Cherkasy, Ukraine, 18009
14	Dnepropetrovsk City Clinical Hospital #4, Regional Hematology Center. Dnepropetrovsk, Ukraine, 49102
15	Ivano-Frankivsk Regional Clinical Hospital. Ivano-Frankivsk, Ukraine, 76008
16	SI Grigoriev Institute for Medical Radiology National Academy of Medical Science of Ukraine. Kharkiv, Ukraine, 61024
17	State Institution ''Scientific Center for Radiation Medicine Academy of Medical Sciences of Ukraine". Kiev, Ukraine, 03115
18	Institute of Blood Pathology and Transfusion Medicine of AMS of Ukraine. Lviv, Ukraine, 79044
19	Mykolaiv Regional Clinical Hospital. Mykolaiv, Ukraine, 54000
20	Ukrainian Medical Stomatological Academy, Poltava Regional Clinical Hospital. Poltava, Ukraine, 36011

Table 11: Bulgaria's myeloma research centres

	Myeloma research centres
1	Military Medical Academy Hospital for Active Treatment. Sofia, Sofiya, Bulgaria
2	Shato, Ead. Sofia, Sofiya, Bulgaria
3	University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD. Plovdiv, Bulgaria
4	Multiprofile Hospital for Active Treatment, "Sveta Marina". Varna, Bulgaria

APPENDICES

Table 12: Romania's myeloma research centres

	Myeloma research centres
1	Spitalul Universitar de Urgenta Bucuresti. Bucharest, Bucuresti, Romania
2	Policlinica de Diagnostic Rapid SA, Compartiment Medical Oncologie-Hematologie. Brasov, Romania
3	Spitalul Clinic Judetean de Urgenta Brasov (Bumbea, Horia). Brasov, Romania
4	Institutul Clinic Fundeni. Bucuresti, Romania
5	Institutul Regional de Oncologie Iasi. Iasi, Romania

Table 13: Lituania's myeloma research centres

	Myeloma research centres
1	Oncology Institute of Lithuanian of Health Sciences. Kaunas, Lithuania, 50009

Table 14: Serbia's myeloma research centres

	Myeloma research centres
1	Clinical Center of Serbia. Belgrade, Serbia, 11000
2	Clinical Hospital Center ''Bezanijska Kosa''. Belgrade, Serbia, 11080
3	Clinical Center Kragujevac. Kragujevac, Serbia, 34000
4	Clinical Center Nis. Nis, Serbia, 18000

Table 15: Slovakia's myeloma research centres

	Myeloma research centres
1	Univerzitná nemocnica Bratislava. Bratislava, Slovakia
2	University Hospital Bratislava - Hospital Ss Cyril and Methodius. Bratislava, Slovakia, 85107

Table 16: Croatia's myeloma research centres

	Myeloma research centres
1	Clinical Hospital Dubrava. Zagreb, Grad Zagreb, Croatia, 10000
2	Clinical Hospital Center Rijeka. Rijeka, Croatia, 51000
3	University Klinichki Bolnicki Centar Zagreb. Zagreb, Croatia, 10 000

Table 17: Estonia's myeloma research centres

	Myeloma research centres
1	Tartu University Hospital Clinic. Tartu, Estonia, 51014

Table 18: Belarus's myeloma research centres

	Myeloma research centres
1	Minsk Scientific Practical Center of Surgery, Transplantation and Hematology. Minsk, Belarus, 220045

APPENDICES

6.2.2. TRIALS ENROLLING CEE PATIENTS BETWEEN 1 JANUARY 2001 AND 28 SEPTEMBER 2020

Of the 46 trials, which had published enrolment data, 17 international trials registered with the European Union Clinical Trial Register (EU CTR) had CEE patients, while 12 international trials on the US National Library of Medicine (NLM) database also included CEE patients. Seventeen trials including only CEE patients were also registered with the EU CTR (4 trials) and the NLM (13 trials).

APPENDICES

Table 19: European Union Clinical Trial register: 17 myeloma international trials including CEE patients

	EUC-TR2008-003752-30	EUC-TR2006-006050-10	EUC-TR2015-005105-36	EUC-TR2006-001865-41	EUC-TR2006-001904-36	EUC-TR2008-004264-39	EUC-TR2009-015507-52	EUC-TR2009-016138-29	EUC-TR2009-016839-35	EUC-TR2009-016840-38	EUC-TR2010-023343-16	EUC-TR2010-023772-71	EUC-TR2011-004783-30	EUC-TR2011-004795-11	EUC-TR2014-002749-23	EUC-TR2015-002993-19	EUC-TR2016-003097-41
Poland	12	10		33	30		21	4	35	16				10			12
Czech Republic	33	16	23	36	24	14	13	33	78	35		15			9		28
Russian Federation	7			20	48		17		48	9	3					50	13
Hungary	2	9			20				79	42							7
Serbia									20	3							
Slovakia										2							1
Lithuania													7				
Ukraine				15													
Estonia													5				
Romania	10				13				16								
Slovenia																	
Croatia	13																
Bulgaria	35				26				57								
Latvia																	
Belarus				5													
Macedonia																	
Bosnia & Herzegovina																	
Moldova																	
Georgia				20													
Albania																	
Montenegro																	
Armenia																	
Azerbaijan																	
Total	112	35	23	129	161	14	51	37	333	107	3	15	12	10	9	50	61

APPENDICES

Table 20: US National Library of Medicine database: 12 international trials including CEE patients

	NCT00103506	NCT00555906	NCT00434161	NCT01335685	NCT03277105	NCT00908232	NCT00911859	NCT01564537	NCT02076009	NCT02181413	NCT02195479	NCT02902965
Poland	52	30			65	19	16	41	28	15	66	
Czech Republic	36	24	18	15	36			36		42	50	23
Russian Federation	72	48			55		20	39	48		43	
Hungary		20	47			2		39		25	26	
Serbia						15					10	
Slovakia												
Lithuania						9						
Ukraine					47					3	48	
Estonia												
Romania		13					2	12			28	
Slovenia												
Croatia											4	
Bulgaria		26									23	
Latvia												
Belarus												
Macedonia											11	
Bosnia & Herzegovina												
Moldova												
Georgia											22	
Albania												
Montenegro												
Armenia												
Azerbaijan												
Total	160	161	65	15	203	45	38	167	76	85	331	23

APPENDICES

Table 21: US National Library of Medicine database and European Union Clinical Trial register: 17 trials including only CEE patients

	NCT 00360347	NCT 00622336	NCT 00747123	NCT 00937183	NCT 01665014	NCT 01908621	NCT 02024815	NCT 02270307	NCT 02452099	NCT 03292263	NCT 03619252	NCT0 3697655	NCT 04242121	EUC-TR2004-001178-13	EUC-TR2017-003253 41	EUC-TR2018-000813 -19	EUC-TR2006-006111-77
Study start date	2001-11	2003-04	2008-09	2003-09	2012-08	2013-03	2011-09	2014-01	2014-01	2017-04	2018-07	2018-12	2020-01	2005-02	2018-11	2019-09	2007-05
Study lead affiliation	Industry	Industry	Industry	Academics	Academics	Academics	Academics	Govern-ment	Academics	Academics	Hospital	Charity	Academics	Industry	Charity	Industry	Industry
Poland	63			12	50	90			150			274			274		
Czech Republic														720		68	25
Russian Federation		330	30					40		30			100				
Hungary																	
Serbia																	
Slovakia																	
Lithuania							100							20			
Ukraine																	
Estonia																	
Romania																	
Slovenia																	
Croatia																	
Bulgaria																	
Latvia														10			
Belarus											40						
Macedonia																	
Bosnia & Herzegovina																	
Moldova																	
Georgia																	
Albania																	
Montenegro																	
Armenia																	
Azerbaijan																	
TOTAL	63	330	30	12	50	90	100	40	150	30	40	274	100	750	274	68	25

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
1	EUCTR2008-003752-30	An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK-0683) or Placebo in Combination with Bortezomib in Patients with Multiple Myeloma	Merck & Co., Inc	2008-11	2015-06	Completed	79	Yes	750	Vorinostat	Placebo + bortezomib	Phase 3	Randomized	NA	WHO
2	NCT00103506	A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma	Janssen Research & Development, LLC	2004-12	2014-06	Completed	114	Yes	646	doxorubicin HCL Liposome Injection + bortezomib	Bortezomib	Phase 3	Randomized	NA	NCT
3	NCT00424047	A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.	Celgene	2003-01	2013-11	Completed	130	Yes	351	CC-5013 + dexamethasone	dexamethasone + placebo	Phase 3	Randomized	NA	NCT
4	NCT00434161	A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation	Swedish Orphan Biovitrum	2006-12	2012-05	Completed	65	Yes	281	Palifermin	Placebo	Phase 3	Randomized	NA	NCT
5	NCT00441168	A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Safety and Efficacy of Velcade When Added to Adriamycin-Dexamethasone Treatment Versus Vincristine-Adriamycin-Dexamethasone Standard Treatment in Subjects With Multiple Myeloma Who Are Refractory to or Have Relapsed After Primary Therapy for Multiple Myeloma	Janssen-Cilag International NV	2006-12	2008-01	Terminated	13	Yes	30	Bortezomib + adriamycin-dexamethasone	Vincristine + adriamycin + Dexamethasone	Phase 2	Randomized	NA	NCT
6	NCT00555906	Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma	Pfizer	2008-01	2013-03	Completed	62	Yes	53	Pd 0332991 + bortezomib + dexamethasone	Dexamethasone	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
7	NCT00608907	An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)	Millennium Pharmaceuticals, Inc.	2007-09	2010-04	Completed	31	Yes	61	Bortezomib + CYP3A4	Bortezomib + rifampicin	Phase 1	Non-randomized	NA	NCT
8	NCT00622336	Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010	Celgene	2003-04	2013-11	Completed	127	Yes	330	CC-5013 + lenalidomide	Lenalidomide	Phase 3	Non-randomized	NA	NCT
9	NCT00656305	A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Treatment of Metastatic and Multiple Myeloma Bone Tumors for the Palliation of Pain in Patients Who Are Not Candidates for Radiation Therapy	InSightec	2008-03	2012-09	Completed	54	Yes	147	ExAblate MRfFUS	Sham	Phase 3	Non-randomized	QoL (Secondary)	NCT
10	NCT00908232	Efficacy and Safety of Velcade Plus Dexamethasone (VD), VD+Cyclophosphamide or VD Plus Lenalidomide in MMY Patients Who Are Refractory or Have Relapsed After Their Primary Therapy for MMY and Have Achieved Stable Disease After 4 Cycles of VD	Janssen-Cilag International NV	2008-05	2011-08	Completed	39	Yes	163	Bortezomib + dexamethasone (VD)	VD + cyclophosphamide or VD + lenalidomide	Phase 2	Non-randomized	NA	NCT
11	NCT00911859	A Randomized, Open-Label, Phase 2 Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone Compared With VELCADE-Melphalan-Prednisone for the Treatment of Previously Untreated Multiple Myeloma	Janssen Research & Development, LLC	2009-06	2013-04	Completed	46	Yes	118	CNTO 328 + bortezomib + melphalan + prednisone	Bortezomib + melphalan + prednisone	Phase 2	Randomized	NA	NCT
12	NCT00950911	An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma	Amgen	2009-07	2012-04	Completed	33	Yes	35	Denosumab	NA	Phase 3	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
13	NCT01023308	A Multicenter, Randomized, Double Blind, Placebo Controlled Phase III Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma	Novartis Pharmaceuticals	2009-12	2015-07	Completed	67	Yes	767	Panobinostat + bortezomib + dexamethasone	Bortezomib	Phase 3	Randomized	NA	NCT
14	NCT01080391	A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma	Amgen	2010-07	2017-12	Completed	89	Yes	792	Carfilzomib + lenalidomide + dexamethasone (CRd)	Lenalidomide + dexamethasone (Rd)	Phase 3	Randomized	NA	NCT
15	NCT01239797	Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)	Bristol-Myers Squibb	2011-03	2020-09	Unknown	114	Yes	761	Elotuzumab + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
16	NCT01286077	A Phase 2, Multicentre, Randomised, Open-Label, Parallel Group Study to Evaluate the Effect of VELCADE on Myeloma Related Bone Disease	Janssen-Cilag International NV	2009-09	2014-04	Completed	55	Yes	106	Bortezomib	Observation	Phase 2	Randomized	NA	NCT
17	NCT01302392	A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma	Amgen	2010-09	2015-09	Completed	60	Yes	315	Carfilzomib	Best supportive care	Phase 3	Randomized	NA	NCT
18	NCT01311687	A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma	Celgene	2011-03	2017-08	Completed	77	Yes	455	Pomalidomide + low-dose dexamethasone	dexamethasone high dose	Phase 3	Randomized	NA	NCT
19	NCT01324947	Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003	Celgene	2011-03	2014-07	Completed	40	Yes	74	Pomalidomide	NA	Phase 3	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
20	NCT01345019	A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma	Amgen	2012-05	2019-03	Completed	82	Yes	1718	Denosumab	Zoledronic acid	Phase 3	Randomized	NA	NCT
21	NCT01564537	A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral Ixazomib (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma	Millennium Pharmaceuticals, Inc.	2012-08	2020-12	Ongoing	100	Yes	722	Ixazomib + lenalidomide + dexamethasone	Placebo + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
22	NCT01602224	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma	Eli Lilly and Company	2012-07	2014-07	Completed	24	Yes	220	Tabalumab + bortezomib + dexamethasone	Placebo + bortezomib + dexamethasone	Phase 2	Randomized	NA	NCT
23	NCT01818752	A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma	Amgen	2013-07	2016-11	Completed	40	Yes	955	Carfilzomib + melphalan + prednisone	Bortezomib + melphalan + prednisone	Phase 3	Randomized	NA	NCT
24	NCT02076009	Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma	Janssen Research & Development, LLC	2014-05	2021-08	Ongoing	87	Yes	569	Daratumumab + lenalidomide + dexamethasone (DRd)	Lenalidomide + dexamethasone (Rd)	Phase 3	Randomized	NA	NCT
25	NCT02181413	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant	Millennium Pharmaceuticals, Inc.	2014-07	2025-06	Ongoing	131	Yes	656	Ixazomib	Placebo	Phase 3	Randomized	NA	NCT
26	NCT02195479	A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy	Janssen Research & Development, LLC	2014-12	2021-10	Ongoing	82	Yes	706	Bortezomib + melphalan + prednisone (VMP)	Daratumumab + VMP (D-VMP)	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
27	NCT02412878	A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing	Amgen	2015-09	2019-01	Completed	40	Yes	478	Carfilzomib + dexamethasone once weekly	Carfilzomib + dexamethasone twice weekly	Phase 3	Randomized	NA	NCT
28	NCT02548962	A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma	Pharmacyclics LLC.	2016-03	2018-06	Terminated	27	Yes	11	Ibrutinib + pomalidomide + dexamethasone	Placebo + pomalidomide + dexamethasone	Phase 1/ Phase 2	Randomized	NA	NCT
29	NCT02579863	A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).	Merck Sharp & Dohme Corp.	2015-10	2020-07	Completed	57	Yes	310	Pembrolizumab + lenalidomide + low-dose dexamethasone	Lenalidomide + low-dose dexamethasone	Phase 3	Randomized	NA	NCT
30	NCT02902965	An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma	Pharmacyclics Switzerland GmbH	2016-09	2018-10	Completed	25	Yes	74	Ibrutinib + bortezomib + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT
31	NCT02990338	A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma	Sanofi	2016-12	2022-03	Ongoing	63	Yes	307	Isatuximab + pomalidomide + low-dose dexamethasone	Pomalidomide + Low-dose dexamethasone	Phase 3	Randomized	NA	NCT
32	NCT00256776	A Randomized Controlled Study of Velcade (Bortezomib) Plus Thalidomide Plus Dexamethasone Compared to Thalidomide Plus Dexamethasone for the Treatment of Myeloma Patients Progressing or Relapsing After Autologous Transplantation	European Group for Blood and Marrow Transplantation	2005-07	2013-06	Unknown	95	No	269	Bortezomib + thalidomide + dexamethasone	Thalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
33	NCT00902915	Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure	Austrian Forum Against Cancer	2009-05	2014-05	Unknown	60	No	50	Lenalidomide + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
34	NCT01335399	A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma	Bristol-Myers Squibb	2011-05	2020-09	Ongoing	112	No	750	Elotuzumab + lenalidomide + dexamethasone	Placebo + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
35	NCT01335685	An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of Ixazomib (MLN9708), a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment	Millennium Pharmaceuticals, Inc.	2011-06	2016-12	Completed	66	Yes	164	Ixazomib + melphalan + prednisone	NA	Phase 1/ Phase 2	Non-randomized	NA	NCT
36	NCT01592370	Multiple Phase 1/2 Cohorts of Nivolumab Monotherapy or Nivolumab Combination Regimens Across Relapsed/Refractory Hematologic Malignancies	Bristol-Myers Squibb	2012-06	2022-01	Ongoing	115	No	375	Nivolumab	Nivolumab combination regimens	Phase 1/ Phase 2	Non-randomized	NA	NCT
37	NCT01734928	A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	Celgene	2013-01	2022-05	Ongoing	112	No	559	Pomalidomide + bortezomib + low-dose dexamethasone	Bortezomib + low-dose dexamethasone	Phase 3	Randomized	NA	NCT
38	NCT01850524	A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma	Millennium Pharmaceuticals, Inc.	2013-05	2021-02	Ongoing	93	No	701	Ixazomib + lenalidomide + dexamethasone	Placebo + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
39	NCT01891643	A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma	Bristol-Myers Squibb	2013-09	2020-07	Unknown	82	No	750	Elotuzumab + lenalidomide + dexamethasone	Lenalidomide + dexamethasone (Rd)	Phase 3	Randomized	NA	NCT
40	NCT02312258	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Millennium Pharmaceuticals, Inc.	2015-04	2024-10	Ongoing	114	No	706	Ixazomib	Placebo	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
41	NCT02316106	A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma	Janssen Research & Development, LLC	2015-05	2021-08	Ongoing	75	No	123	Daratumumab	Daratumumab different doses	Phase 2	Randomized	NA	NCT
42	NCT02514668	An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma	Sanofi	2015-09	2020-12	Ongoing	63	No	55	Isatuximab	NA	Phase 1	Non-randomized	NA	NCT
43	NCT02572492	Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT	Aalborg University Hospital	2015-01	2019-04	Unknown	51	No	200	Carfilzomib/ dexamethasone maintenance	Observation	Phase 2	Randomized	NA	NCT
44	NCT02654990	A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents	SecuraBio	2016-04	2024-05	Ongoing	97	No	249	Panobinostat + subcutaneous bortezomib + oral dexamethasone	Three different regimens	Phase 2	Randomized	NA	NCT
45	NCT02726581	An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma	Bristol-Myers Squibb	2016-04	2021-03	Ongoing	59	No	348	Nivolumab + pomalidomide + dexamethasone	Different combinations	Phase 3	Randomized	NA	NCT
46	NCT02924272	An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies	Millennium Pharmaceuticals, Inc.	2016-12	2021-10	Ongoing	58	No	31	Ixazomib	NA	Phase 2	Non-randomized	NA	NCT
47	NCT03110562	A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)	Karyopharm Therapeutics Inc	2017-05	2023-09	Ongoing	76	No	402	Selinexor + bortezomib + dexamethasone (SVd)	Bortezomib + dexamethasone (Vd)	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
48	NCT03136653	A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma	Molecular Partners AG	2017-05	2023-07	Ongoing	74	No	33	MP0250 + bortezomib + dexamethasone	NA	Phase 1/ Phase 2	Non-randomized	NA	NCT
49	NCT03158688	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma	Amgen	2017-06	2022-07	Ongoing	61	Yes	466	Carfilzomib + dexamethasone + daratumumab	Carfilzomib + dexamethasone	Phase 3	Randomized	NA	NCT
50	NCT03170882	A Phase 2, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma	Millennium Pharmaceuticals, Inc.	2017-08	2020-09	Ongoing	37	No	120	Ixazomib + dexamethasone	Pomalidomide + dexamethasone	Phase 2	Randomized	NA	NCT
51	NCT03180736	A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.	European Myeloma Network	2017-06	2024-04	Ongoing	82	No	304	Daratumumab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
52	NCT03194867	A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma	Sanofi	2018-02	2021-04	Ongoing	38	No	109	Isatuximab + cemiplimab	Different combinations	Phase 1/ Phase 2	Non-randomized	NA	NCT
53	NCT03275285	Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines	Sanofi	2017-10	2023-02	Ongoing	64	No	302	Isatuximab + carfilzomib + dexamethasone	Carfilzomib + dexamethasone	Phase 3	Randomized	NA	NCT
54	NCT03277105	A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma	Janssen Research & Development, LLC	2017-10	2024-03	Ongoing	77	Yes	522	Subcutaneous daratumumab	Intravenous daratumumab	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
55	NCT03301220	A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma	Janssen Research & Development, LLC	2017-11	2025-12	Ongoing	97	No	389	Subcutaneous daratumumab	Observation	Phase 3	Randomized	NA	NCT
56	NCT03312530	A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma	Hoffmann-La Roche	2017-11	2020-10	Ongoing	35	No	72	Cobimetinib	Cobimetinib + venetoclax +/- atezolizumab	Phase 1/ Phase 2	Non-randomized	NA	NCT
57	NCT03319667	A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant	Sanofi	2017-12	2025-01	Ongoing	85	No	475	Isatuximab + bortezomib + lenalidomide + dexamethasone	Bortezomib + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
58	NCT03412565	A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens	Janssen Research & Development, LLC	2018-04	2021-11	Ongoing	43	No	265	Subcutaneous daratumumab	Bortezomib + daratumumab	Phase 2	Non-randomized	NA	NCT
59	NCT03439293	A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)	Millennium Pharmaceuticals, Inc.	2018-03	2022-09	Ongoing	54	No	61	Ixazomib + daratumumab + dexamethasone (IDd)	NA	Phase 2	Non-randomized	NA	NCT
60	NCT03652064	A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Janssen Research & Development, LLC	2018-11	2025-04	Ongoing	77	No	395	Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd)	Bortezomib + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
61	NCT03710603	A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Previously Untreated Multiple Myeloma Who Are Eligible for High-dose Therapy	European Myeloma Network	2018-12	2029-11	Ongoing	131	No	690	Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd)	Bortezomib + lenalidomide + dexamethasone	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
62	NCT02477891	An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent	Janssen Research & Development, LLC	2015-08	2020-02	Completed	54	No	470	Daratumumab	NA	Early Access	Non-randomized	NA	NCT
63	EUCTR2004-001989 -41	An Open-Label, Randomized Study of VELCADE/Melphalan/Prednisone versus Melphalan/Prednisone in subjects with previously untreated Multiple Myeloma. - Velcade-MMY-3002	Janssen-Cilag S.A.	2005-02	2011-04	Completed	74	Yes	680	Dacortin	Melphalan + prednisone	Phase 3	Randomized	EORTC QLQ-C30	WHO
64	EUCTR2005-003001-85	Bortezomib-Doxorubicin-Dexamethasone (BDD) as Treatment for Patients with Multiple Myeloma Presenting with Acute Renal Failure - BDD	Austrian Forum against Cancer	2006-11	2009-11	Completed	36	Yes	50	Bortezomib	NA	Phase 2	Non-randomized	NA	WHO
65	EUCTR2006-000848-65	Estudio multicéntrico, aleatorizado y doble ciego de denosumab en comparación con ácido zoledrónico (Zometa®) en el tratamiento de metástasis óseas, en sujetos con cáncer avanzado o mieloma múltiple (excluyendo cáncer de mama y de próstata)	Amgen Inc	2006-09	2011-08	Completed	59	Yes	1690	Denosumab	Zolendronic acid	Phase 3	Randomized	NA	WHO
66	EUCTR2006-006050-10	A Phase 2, Randomized Study of VELCADE (bortezomib), Dexamethasone and Thalidomide versus VELCADE (bortezomib), Dexamethasone, Thalidomide and Cyclophosphamide in Subjects with Previously Untreated Multiple Myeloma who are Candidates for Autologous Transplantation - ND	JANSSEN-CILAG INTERNATIONAL NV	2008-04	2013-10	Completed	66	Yes	97	Bortezomib + dexamethasone + thalidomide	Bortezomib + dexamethasone + thalidomide + cyclophosphamide	Phase 2	Randomized	NA	WHO
67	EUCTR2007-004138-17	Ensayo Clínico fase 3, aleatorizado, en régimen abierto de Tanespimicina (KOS-953) más Bortezomib en comparación con Bortezomib solo, en pacientes con Mieloma Múltiple en primera recaída. Phase 3 Randomized, Open-Label Clinical Trial of Tanespimycin (KOS-953) plus Bortezomib Compared to Bortezomib Alone in Patients with Multiple Myeloma in First Relapse	KOSAN BIOSCIENCES, INC.	2008-04	2010-03	Completed	23	Yes	466	Tanespimycin (KOS-953) + bortezomib	Bortezomib	Phase 3	Randomized	QoL (Primary)	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
68	EUCTR2008-006497-15	Lenalidomide and Dexamethasone for treatment of patients with acute myeloma (light chain)-induced renal failure	Wilhelminen Krebsforschung GmbH	2012-05	2012-12	Completed	7	Yes	50	Lenalidomide + dexamethasone	NA	Phase 2	Non- randomized	NA	WHO
69	EUCTR2008-008599-15	A Phase 3, Multicentre, Randomized, Controlled Study To Determine The efficacy And Safety Of Cyclophosphamide, Lenalidomide And Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Stem Cell Transplant In Newly Diagnosed Multiple Myeloma Subjects	Fondazione Neoplasie Sangue Onlus	2010-08	NA	Ongoing	NA	NA	380	Cyclophosphamide + lenalidomide + dexamethasone	Malphalan followed by stem cell transplant	Phase 3	Non- randomized	NA	WHO
70	EUCTR2008-008606-52	A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomide In Combination With Dexamethasone (Rd) Versus Melphalan, Prednisone And Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone And Lenalidomide (CPR) in Newly Diagnosed Multiple Myeloma Subjects - ND	Fondazione Neoplasie Sangue Onlus	2009-03	NA	Ongoing	NA	NA	660	Lenalidomide + dexamethasone	Melphalan + prednisone + lenalidomide (MPR) vs. cyclophosphomide + prednisone + lenalidomide (CPR)	Phase 3	Randomized	NA	WHO
71	EUCTR2009-017237-22	A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma	Centocor B.V.	2011-02	2011-09	Terminated	7	No	500	Siltuximab	Placebo + bortezomib + dexamethasone	Phase 3	Randomized	NA	WHO
72	EUCTR2009-017903-28	A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma - HOVON 95 MM	HOVON Foundation	2010-08	NA	Ongoing	NA	NA	1500	Bortezomib + melphalan + prednisone (VMP)	High dose melphalan followed by Bortezomib + lenalidomide + dexamethasone (VRD) consolidation and Lenalidomide maintenance	Phase 3	Randomized	NA	WHO
73	EUCTR2010-020347-12	A Phase 3, Randomized, Open Label Trial of Lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma	Bristol Myers Squibb International Corporation	2011-07	NA	Ongoing	NA	NA	640	Elotuzumab + lenalidomide + dexamethasone	Lenalidomide + lexamethasone	Phase 3	Randomized	EORTC QLQ-C30, QLQ MY20	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
74	EUC-TR2013-000326-54	Study to determine whether adding MLN9708 to the combination of lenalidomide and dexamethasone improves survival in patients who have been newly diagnosed with multiple myeloma and have not received previous anti-myeloma treatment	Millennium Pharmaceuticals, Inc.	2013-06	NA	Ongoing	NA	NA	701	MLN9708 + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 3	Randomized	NA	WHO
75	EUC-TR2013-003265-34	Pomalidomide combined with Carfilzomib and Dexamethasone (PCd) for induction and consolidation followed by Pomalidomide combined with Dexamethasone vs Pomalidomide maintenance for patients with Multiple Myeloma in progression after prior 1st line treatment with Lenalidomide and Bortezomib.	HOVON Foundation	2015-05	NA	Ongoing	NA	NA	222	Pomalidomide + carfilzomib + dexamethasone (PCd)	Pomalidomide maintenance	Phase 2	Randomized	QoL (Primary), QoL (Secondary)	WHO
76	EUC-TR2013-003789-15	Phase II study of carfilzomib- cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observa-tion or maintenance with carfil-zomib and dexamethasone in pa-tients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support	Nordic Myeloma Study Group	2016-10	NA	Ongoing	NA	NA	200	Carfilzomib + cyclophosphamide + dexamethasone + high-dose melphalan	Carfilzomib + cyclophosphamide + dexamethasone + high-dose melphalan	Phase 2	Randomized	QoL (Primary), QoL (Secondary)	WHO
77	EUC-TR2013-005525-23	A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma	Janssen-Cilag International N.V.	2014-05	NA	Ongoing	NA	NA	560	Daratumumab + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 3	Randomized	NA	WHO
78	EUC-TR2014-000255-85	Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma	Janssen-Cilag International N.V.	2014-10	NA	Ongoing	NA	NA	480	Daratumumab + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	Eq-5d (Primary), Patient reported outcome(s) (Primary), EORTC QLQ-C30	WHO
79	EUC-TR2014-001394-13	Study to determine whether ixazomib as maintenance therapy has an effect on progression free survival and compared to placebo in patients with newly diagnosed multiple myeloma who have not been treated with stem-cell transplantation	Millennium Pharmaceuticals, Inc.	2015-03	NA	Ongoing	NA	NA	706	Ixazomib	Placebo	Phase 3	Randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
80	EUCTR2014-002272-88	A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants with Previously Untreated Multiple Myeloma	Janssen-Cilag International N.V.	2015-02	NA	Ongoing	NA	NA	700	Daratumumanb + bortezomib + melphalan-prednisone (DVMP)	Bortezomib + melphalan + prednisone (VMP)	Phase 3	Randomized	Patient reported outcome(s) (Primary)	WHO
81	EUCTR2014-003282-19	Pomalidomide/Dexamethasone With or Without Elotuzumab in Multiple Myeloma that is resistant to treatment.	Bristol-Myers Squibb International Corporation	2016-09	NA	Ongoing	NA	NA	150	Elotuzumab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 2	Randomized	NA	WHO
82	EUCTR2014-005139-14	A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants with Smoldering Multiple Myeloma	Janssen-Cilag International N.V.	2015-11	NA	Ongoing	NA	NA	62	Daratumumab	Three doses	Phase 2	Randomized	NA	WHO
83	EUCTR2015-001564-19	Panobinostat with bortezomib and dexamethasone in relapsed or relapsed-and-refractory multiple myeloma	Novartis Pharma Services AG	2016-09	NA	Ongoing	NA	NA	240	Panobinostat + bortezomib + dexamethasone	Three regimens	Phase 2	Randomized	HRQoL (Primary), HRQoL (Secondary), QoL (Primary), EORTC QLQ-C30	WHO
84	EUCTR2015-002380-42	Research study to determine whether a combination of 3 drugs called lenalidomide, carfilzomib and dexamethasone given to persons after autologous stem cell (a young cell without a specific purpose from which other cell types develop) transplant is better than lenalidomide maintenance alone.	Polish Myeloma Consortium	2016-10	NA	Ongoing	NA	NA	180	Lenalidomide + carfilzomib + dexamethasone	Lenalidomide maintenance	Phase 3	Randomized	NA	WHO
85	EUCTR2015-005105-36	A study of Ibrutinib in Combination with Bortezomib and Dexamethasone in Multiple Myeloma Patients	PHARMACYCLICS, INC.	2016-09	2018-10	Completed	25	Yes	125	Ibrutinib + bortezomib + dexamethasone	NA	Phase 2	Non-randomized	NA	WHO
86	EUCTR2015-005699-21	Phase 3 Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma	Bristol-Myers Squibb International Corporation	2017-08	NA	Suspended	NA	NA	512	Nivolumab + elotuzumab + pomalidomide + dexamethasone	Nivolumab + elotuzumab + pomalidomide + dexamethasone or pomalidomide + dexamethasone	Phase 3	Randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
87	EUC-TR2016-001205-16	A clinical study to compare the safety, effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of Daratumumab given through the subcutaneous route versus the active monitoring in patients with high risk smoldering multiple myeloma (precancerous form of blood cancer in the bone marrow)	Janssen-Cilag International N.V.	2018-01	NA	Ongoing	NA	NA	360	Subcutaneous daratumumab	Observation	Phase 3	Randomized	Eq-5d (Secondary), HRQoL (Primary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
88	EUC-TR2016-001681-28	The aim of the study is to provide patients with certain kinds of cancer continued access to the same drug they have received in a previous study, if they have benefited from the use of the drug.	Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited	2017-11	NA	Ongoing	NA	NA	48	Ixazomib	NA	Phase 2	Non-randomized	NA	WHO
89	EUC-TR2016-002771-10	A Phase II open-label (non-blinded), single-arm (same treatment for all participants) multicenter trial of MP0250 plus bortezomib+dexamethasone in patients with multiple myeloma whose disease did not respond to/has recurred after standard treatments	Molecular Partners AG	2019-09	NA	Ongoing	NA	NA	54	MP0250 + bortezomib + dexamethasone	NA	Phase 2	Non-randomized	NA	WHO
90	EUC-TR2016-003517-95	Multicenter study to compare the combination of Melflufen/ Dexamethasone vs.Pomalidomide/Dexamethasone in patients with Relapsed Refractory Multiple Myeloma.	Oncopeptides AB	2018-05	NA	Ongoing	NA	NA	450	Melflufen + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	NA	WHO
91	EUC-TR2016-003554-33	A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the treatment of Patients With Relapsed or Refractory Multiple Myeloma	Amgen Inc	2017-08	NA	Ongoing	NA	NA	450	Carfilzomib + dexamethasone + daratumumab	Carfilzomib + dexamethasone	Phase 3	Randomized	NA	WHO
92	EUC-TR2016-003957-14	Bortezomib, Selinexor and Dexamethasone in Patients with Multiple Myeloma	Karyopharm Therapeutics Inc.	2017-04	NA	Ongoing	NA	NA	364	Bortezomib + selinexor + dexamethasone	Different combinations	Phase 3	Randomized	Eq-5d (Secondary), EORTC QLQ-C30	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
93	EUCTR2016-004742-28	Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma	Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda	2018-03	NA	Ongoing	NA	NA	122	Ixazomib + dexamethasone	Oral Pomalidomide + dexamethasone	Phase 2	Randomized	Eq-5d (Primary), Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
94	EUCTR2017-000206-38	A clinical study to compare the effectiveness and pharmacokinetics (the way the body absorbs, distributes, and gets rid of a drug) of Daratumumab given through the subcutaneous route versus the intravenous route in patients with relapsed or refractory multiple myeloma (blood cancer in the bone marrow)	Janssen-Cilag International N.V.	2017-08	NA	Ongoing	NA	NA	480	Subcutaneous daratumumab	Intravenous daratumumab	Phase 3	Randomized	NA	WHO
95	EUCTR2017-000555-10	Carfilzomib, Lenalidomide and Dexamethasone versus Lenalidomide and Dexamethasone in High- Risk Smoldering Multiple Myeloma.	HOVON Foundation	2018-06	NA	Ongoing	NA	NA	120	Carfilzomib + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 2	Randomized	NA	WHO
96	EUCTR2017-000830-68	A Study of Cobimetinib Administered as Single Agent and in Combination with Venetoclax, with or Without Atezolizumab, in Patients with Relapsed and Refractory Multiple Myeloma	F. Hoffman-La Roche Ltd.	2018-05	NA	Ongoing	NA	NA	72	Cobimetinib	Cobimetinib + Venetoclax +/- atezolizumab	Phase 1/ Phase 2	Randomized	NA	WHO
97	EUCTR2017-001431-39	Isatuximab in Combination with Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients	Sanofi-aventis recherche & developpement	2018-12	NA	Ongoing	NA	NA	123	Isatuximab + Cemiplimab	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
98	EUCTR2017-001618-27	Study to compare Pomalidomide and Dexamethasone With or Without Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.	European Myeloma Network (EMN)	2018-02	NA	Ongoing	NA	NA	302	Daratumumab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	Eq-5d (Secondary), HRQoL (Primary), QoL (Primary), EORTC QLQ-C30	WHO
99	EUCTR2017-002120-24	It is an early clinical trial to assess a new drug (Melflufen) when given together with a steroid (Dexamethasone) and an approved drug (either Bortezomib or Daratumumab) in the treatment of patients with the cancer (MM) which returns after treatment and is not responded to treatment	Oncopeptides AB	2017-12	NA	Ongoing	NA	NA	80	Melflufen + dexamethasone + bortezomib or daratumumab	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
100	EUC-TR2017-002611-34	A multiphase study assessing the anti-tumor activity and safety of JNJ-63723283 (an Anti-PD-1 monoclonal antibody) administered in combination with daratumumab, compared with daratumumab alone in subjects with relapsed or refractory Multiple Myeloma.	Janssen-Cilag International N.V.	2017-10	NA	Ongoing	NA	NA	386	JNJ-63723283 + daratumumab	Daratumumab	Phase 2/ Phase 3	Randomized	Eq-5d (Primary), Eq-5d (Secondary), QoL (Primary), EORTC QLQ-C30	WHO
101	EUC-TR2017-003253-41	Clinical Trial conduct to investigate if Daratumumab therapy for multiple myeloma patients with minimal residual disease (MRD) reappearance or biochemical relapse is effective in preventive therapy.	Polish Myeloma Consortium	2018-11	NA	Ongoing	NA	NA	274	Daratumumab	Observation	Phase 2	Randomized	QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
102	EUC-TR2018-000478-31	Multicenter study to assess Pharmacokinetics of Melphalan During Treatment with Melflufen and Dexamethasone	Oncopeptides AB	2019-12	NA	Ongoing	NA	NA	40	Melphalan + melflufen + dexamethasone	NA	Phase 2	Non-randomized	NA	WHO
103	EUC-TR2018-000665-36	A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination with Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	Amgen Inc	2019-09	NA	Ongoing	NA	NA	460	Carfilzomib + lenalidomide + dexamethasone	Carfilzomib + lenalidomide + dexamethasone	Phase 3	Randomized	NA	WHO
104	EUC-TR2018-001545-13	A Clinical Study to Compare Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Bone Marrow Cancer and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	Janssen-Cilag International N.V.	2019-01	NA	Ongoing	NA	NA	360	Daratumumab + bortezomib + lenalidomide + dexamethasone (D-VRd)	Bortezomib + lenalidomide + dexamethasone (VRd)	Phase 3	Randomized	NA	WHO
105	EUC-TR2018-002089-37	A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-Dexamethasone (Dara-VCD) versus The Association Of Bortezomib-Thalidomide-Dexamethasone (VTD) As Pre Transplant Induction And Post Transplant Consolidation, Both Followed By A Maintenance Phase With Ixazomib Alone Or In Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible For Autologous Stem Cell Transplantation	European Myeloma Network	2019-08	NA	Ongoing	NA	NA	400	DARATUMUMAB + BORTEZOMIB-CYCLOPHOSPHAMIDE-DEXAMETHASONE (Dara-VCd)	Bortezomib + thalidomide + dexamethasone (VTd)	Phase 2	Randomized	QoL (Primary)	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
106	EUCTR2018-004252-38	A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma	GlaxoSmithKline Research & Development Ltd	2020-06	NA	Ongoing	NA	NA	320	Belantamab mafodotin	Pomalidomide + dexamethasone	Phase 3	Randomized	HRQoL (Primary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
107	EUCTR2018-004767-31	A Trial to Determine the Recommended Dose, Dosing Pattern, Effectiveness and Safety of CC-92480 When Combined with Standard Treatments in Patients Who have Non-responsive or Recurrent Myeloma and in Patients Who Have Been Newly Diagnosed with Myeloma.	Celgene Corporation	2019-08	NA	Ongoing	NA	NA	238	CC-92480 + standard treatment	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
108	EUCTR2019-002161-36	A study comparing treatment with Melflufen in combination with Daratumumab and daratumumab treatment only in patients with Relapsed or Relapsed-Refractory Multiple Myeloma	Oncopeptides AB	2020-02	NA	Ongoing	NA	NA	170	Melflufen + daratumumab	Daratumumab	Phase 3	Randomized	Eq-5d (Secondary), Patient reported outcome(s) (Primary), EORTC QLQ-C30,	WHO
109	EUCTR2019-003047-30	A clinical trial of belantamab mafodotin plus standard of care treatments compared with standard of care treatments alone for patients with newly diagnosed multiple myeloma not eligible for transplant	GlaxoSmithKline, S.A.	2020-03	NA	Ongoing	NA	NA	798	Belantamab mafodotin + standard treatments	Standard of care	Phase 3	Randomized	HRQoL (Primary), HRQoL (Secondary), EORTC QLQ-C30	WHO
110	EUCTR2019-003139-47	A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma	Sanofi-Aventis Recherche & Développement	2020-04	NA	Ongoing	NA	NA	500	Isatuximab + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 3	Randomized	Eq-5d (Secondary), EORTC QLQ-C30	WHO
111	EUCTR2019-004127-21	A Phase 2 study comparing the pharmacokinetics and assessing safety and tolerability of peripheral and central intravenous administration of melflufen in patients with relapsed and refractory multiple myeloma.	Oncopeptides AB	2020-08	NA	Ongoing	NA	NA	25	Melflufen	Dexamethasone	Phase 2	Randomized	NA	WHO
112	EUCTR2019-004340-30	Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)	AbbVie Deutschland GmbH & Co. KG	2020-08	NA	Ongoing	NA	NA	120	Venetoclax + carfilzomib + dexamethasone	NA	Phase 2	Non-randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
113	EUCTR2019-004844-32	A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenalidomide-Dexamethasone in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)	European Myeloma Network – EMN	2020-06	NA	Ongoing	NA	NA	300	Isatuximab + carfilzomib + lenalidomide + dexamethasone	Carfilzomib + lenalidomide + dexamethasone	Phase 3	Randomized	Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
114	NCT03246529	A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma - The GENESIS Study	BioLineRx, Ltd.	2018-01	NA	Ongoing	NA	NA	207	BL-8040 + G-GS	Placebo + G-CSF	Phase 3	Randomized	NA	NCT
115	NCT00330759	A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma.	Amgen	2006-06	2012-10	Completed	76	Yes	25	Denosumab	Zolendronic acid	Phase 3	Randomized	NA	NCT
116	NCT00773747	An International, Multicenter, Randomized, Double-Blind Study of Vorinostat (MK0683) or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma	Merck Sharp & Dohme Corp.	2008-12	2015-06	Completed	78	No	10	Vorinostat	Placebo	Phase 3	Non-randomized	NA	NCT
117	PER-020	An Open-Label, Randomized, Multicenter Clinical Study Toinvestigate The Efficacy And Tolerability Of Intravenous Zometa® (Zoledronate) 8 mg in Patients With Metastatic Bone Lesions Due To Breast Cancer Or Multiple Myeloma	Novartis Bioscienses Peru S.A.,	1900-01	NA	Unknown	NA	NA	NA	Zoledronate	Unknown	NA	Randomized	NA	WHO
118	NCT00405756	A Phase III, Multicentre, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study To Determine The Efficacy And Safety Of Lenalidomde (Revlimid®) In Combination With Melphalan And Prednisone Versus Placebo Plus Melphalan And Prednisone In Subjects With Newly Diagnosed Multiple Myeloma Who Are 65 Years Of Age Or Older	Celgene Corporation	2007-01	2016-04	Completed	111	Yes	459	Lenalidomde + melphalan + prednisone	Placebo + melphalan + prednisone	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
119	NCT01568866	A Randomized, Open-label, Phase 3 Study of Carfilzomib Plus Dexamethasone vs. Bortezomib Plus Dexamethasone in Patients With Relapsed Multiple Myeloma	Amgen	2012-06	2018-02	Completed	68	Yes	898	Carfilzomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	NA	NCT
120	CTRI/2011/05/001732	Velcade is being tested in Subcutaneus route as compared to Intravenous route in pateitns with previuosly treated Multiple Myeloma	Johnson and Johnson Limited	2009-11	2009-12	Unknown	1	NA	222	Subcutaneous bortezomib	Intravenous bortezomib	Phase 3	Randomized	NA	WHO
121	NCT00057564	A Multicenter, Randomized, Parallel-group, Double Blind, Placebo-controlled Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone as Induction Therapy for Previously Untreated Subjects With Multiple Myeloma	Celgene Corporation	2003-02	2013-08	Completed	126	No	470	Thalidomide + dexamethasone	Dexamethasone	Phase 3	Randomized	NA	NCT
122	NCT00360347	Open Label, Randomized, Exploratory Study to Investigate the Hemoglobin Dose-response, the Safety and the Pharmacokinetic Profile Following Subcutaneous Administration of Mircera Once Every Three Weeks to Anemic Patients With Multiple Myeloma	Hoffmann-La Roche	2001-11	2003-04	Completed	17	No	63	Mircera	Different doses	Phase 1/ Phase 2	Randomized	NA	NCT
123	NCT00401804	Bortezomib-Doxorubicin-Dexamethasone as Treatment for Patients With Multiple Myeloma Presenting With Acute Renal Failure	Austrian Forum Against Cancer	2006-02	2009-11	Completed	45	No	72	Bortezomib + doxorubicin + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT
124	NCT00452569	Randomised, Controlled, Open-labelled, Multi-centre Comparison of Thalidomide Versus High-dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma	Celgene	2006-02	2009-01	Completed	35	No	499	Thalidomide	Dexamethasone high dose	Phase 3	Randomized	NA	NCT
125	NCT00747123	A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma	Celgene	2008-09	2009-08	Completed	11	No	30	ACE-011 (hActRIIA-IgG1)	Placebo	Phase 2	Randomized	NA	NCT
126	NCT00773838	An International, Multicenter, Open-Label Study of Vorinostat (MK0683) in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma	Merck Sharp & Dohme Corp.	2008-12	2012-04	Completed	40	No	143	Vorinostat + bortezomib	NA	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
127	NCT00937183	Vaccination of Lymphoma Patients With Dendritic Cell-lymphoma Cell Hybrids and Dendritic Cells Pulsed With Tumor Lysates	Maria Sklodowska-Curie Institute - Oncology Center	2003-09	2017-12	Completed	171	No	12	Autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine	NA	Phase 1/ Phase 2	Non-randomized	NA	NCT
128	NCT01102426	Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma	PharmaMar	2010-06	2017-11	Completed	89	No	250	Plitidepsin + dexamethasone	Dexamethasone	Phase 3	Randomized	NA	NCT
129	NCT01168804	Bendamustine Plus Bortezomib Plus Dexamethasone in the Treatment of Stage II/III Relapsed or Refractory Multiple Myeloma	Austrian Forum Against Cancer	2010-06	2013-05	Completed	35	No	79	Bendamustine + bortezomib + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT
130	NCT01219010	A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma	Janssen Research & Development, LLC	2010-10	2014-03	Completed	41	No	30	Siltuximab	NA	Phase 1	Non-randomized	NA	NCT
131	NCT01241396	An Observational Study of the Treatment of Multiple Myeloma in Routine Clinical Practice	Janssen Pharmaceutica N.V., Belgium	2010-10	2014-11	Completed	49	No	2396	Any	NA	NA	Non-randomized	QoL (Secondary)	NCT
132	NCT01753453	A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell (Plasma Cell) Mobilization and Apheresis Product Contamination in Plerixafor Plus Non-pegylated G-CSF Mobilized Patients and in Non-pegylated G-CSF Alone Mobilized Patients	Sanofi	2013-06	2016-09	Completed	39	No	23	Plerixafor	Granulocyte-colony stimulating factor (G-CSF)	Phase 2	Randomized	NA	NCT
133	NCT01908621	Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients.	Maria Sklodowska-Curie Institute - Oncology Center	2013-03	2017-10	Completed	55	No	90	Filgrastim	Intermediate-dose Cytosine Arabinoside + G-CSF	Phase 3	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
134	NCT01910987	A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.	Janssen-Cilag International NV	2013-04	2016-02	Completed	34	No	80	Bortezomib + dexamethasone	Bortezomib + dexamethasone prolonged treatment	Phase 3	Randomized	NA	NCT
135	NCT02046070	An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment	Millennium Pharmaceuticals, Inc.	2014-03	2018-06	Completed	51	Yes	148	Ixazomib + cyclophosphamide + dexamethasone	Different doses	Phase 2	Randomized	NA	NCT
136	NCT02410694	Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma	Arbeitsgemeinschaft medikamentoese Tumortherapie	2015-04	2019-05	Completed	49	No	90	Ixazomib + thalidomide + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT
137	NCT02452099	Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells.	Maria Sklodowska-Curie Institute - Oncology Center	2014-01	2016-12	Completed	35	No	150	Cryopreservation of HSCs using 7,5% DMSO concentration	7% and 10% concentration	NA	NA	NA	NCT
138	NCT03091127	Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.	Amgen	2017-03	2020-03	Completed	36	No	705	Carfilzomib	NA	NA	Non-randomized	NA	NCT
139	NCT02024815	Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma.	Lithuanian University of Health Sciences	2011-09	2015-06	Unknown	45	No	100	One Fraction Radiotherapy (8 Gy x 1)	Multi-fraction radiotherapy (3 Gy x 10)	Phase 3	Randomized	NA	NCT
140	NCT03619252	Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents	Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology	2018-07	2020-12	Ongoing	29	No	40	Pneumococcal conjugate vaccine	Standard antibacterial prophylaxis	Phase 4	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

Nº	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
141	EUCTR2004-001178-13	An International Single-Arm Protocol to Provide Expanded Access to VELCADE(TM) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma - Expanded Access Program to VELCADE	Janssen Cilag International NV	2005-02	2006-10	Completed	20	Yes	750	Bortezomib	NA	Phase 3	Non-randomized	NA	WHO
142	EUCTR2004-001426-24	Multicenter, open, randomized study for first-line treatment of multiple myeloma: thalidomide/dexamethasone vs. MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy - Thal/Dex vs. MP	Wilhelminenspital, First Department of Medicine and Medical Oncology	2004-11	2005-06	Completed	7	Yes	350	Thalidomide + dexamethasone	MP for induction therapy and thalidomide/Intron A vs. Intron A for maintenance therapy	Phase 3	Randomized	QoL (Primary)	WHO
143	EUCTR2005-002756-18	Bortezomib consolidation in patients with myeloma following treatment with high-dose melphalan and autologous stem cell support. A randomised NMSG trial (15/05)	Nordic Myeloma Study Group	2005-12	2010-04	Completed	52	Yes	400	Bortezomib	Standard of care	Phase 3	Randomized	QoL (Primary)	WHO
144	EUCTR2005-003770-23	Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III study	F. Hoffmann-La Roche Ltd	2006-04	NA	Terminated	NA	NA	424	Ibandronic acid	Intravenous zoledronate	Phase 3	Randomized	NA	WHO
145	EUCTR2005-004937-16	Randomised, Controlled, Open-Label, Multi-Centre Comparison of Thalidomide Versus High-Dose Dexamethasone for the Treatment of Relapsed Refractory Multiple Myeloma	Celgene International Sarl	2006-02	2009-01	Completed	35	Yes	496	Thalidomide	Dexamethasone high dose	NA	Randomized	QoL (Primary)	WHO
146	EUCTR2006-001865-41	A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled, 3-Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide (Revlimid) in Combination with Melphalan and Prednisone Versus Placebo Plus Melphalan and Prednisone in Subjects with Newly Diagnosed Multiple Myeloma Who Are 65 Years of Age or Older	Celgene International Sàrl	2007-02	2016-04	Completed	110	Yes	450	Lenalidomide + melphalan + prednisone	Placebo + melphalan + prednisone	Phase 3	Randomized	NA	WHO
147	EUCTR2006-001904-36	A Phase 2, Randomized, Double-blind, Placebo-controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade® versus Velcade alone in Subjects with Relapsed or Refractory Multiple Myeloma	Centocor B.V.	2006-07	2019-09	Completed	158	Yes	290	CNTO 328 + bortezomib	Bortezomib	Phase 2	Randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
148	EUCTR2006-003709-15	A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin (Pre- and Post Chemotherapy and Pre-Chemotherapy only) for Reduction in Severity of Oral Mucositis in Subjects with Multiple Myeloma (MM) Receiving High Dose Melphalan followed by Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)	AMGEN S.P.A.	2006-12	2011-11	Completed	59	Yes	275	Palifermin pre/post chemo	Palifermin pre chemo	Phase 3	Randomized	NA	WHO
149	EUCTR2006-006111-77	An open-label phase II study evaluating the safety and efficacy of induction analgesic therapy with ibandronic acid (Bondronat) administered intravenously over 15 minutes at a dose of 6 mg 3 for consecutive days to patients with multiple myeloma. Otevrená studie fáze II hodnotící bezpecnost a úcinnost indukcní analgetické lécby kyselinou ibandronovou (Bondronat) podávanou intravenózne po dobu 15 minut v dávce 6 mg 3 po sobe následující dny pacientum s mnohocetným myelomem.	Roche s.r.o.	2007-05	2008-09	Completed	16	NA	25	Ibandronic acid	NA	Phase 2	Non-randomized	NA	WHO
150	EUCTR2009-015507-52	Estudio Fase III, multicéntrico, aleatorizado, doble ciego, controlado con placebo, de panobinostat en combinación con bortezomib y dexametasona, en pacientes con mieloma múltiple en recaída	Novartis Farmacéutica S.A.	2010-02	2015-07	Completed	65	Yes	750	Panobinostat + bortezomib + dexamethason	Placebo + bortezomib + dexamethason	Phase 3	Randomized	NA	WHO
151	EUCTR2009-016138-29	Phase III, Randomized, Multicenter and Open Study of Plitidepsin in combination with Dexamethasone vs. Dexamethasone alone in patients with Refractory or Relapsed Multiple Myeloma. - ADMYRE. Estudio de Fase III, Aleatorizado, Multicéntrico y Abierto de Plitidepsina en combinación con Dexametasona vs. Dexametasona sola en pacientes con Mieloma Múltiple Refractario o en Recaída. - ADMYRE	Pharma Mar, S.A.	2010-05	2018-11	Completed	102	Yes	250	Plitidepsin + dexamethasone	Dexamethasone	Phase 3	Randomized	NA	WHO
152	EUCTR2009-016839-35	A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed Multiple Myeloma	Onyx Therapeutics, Inc.	2010-07	2017-12	Completed	89	Yes	770	Carfilzomib + lenalidomide + dexamethasone (CRd)	Lenalidomide + dexamethasone (Rd)	Phase 3	Randomized	NA	WHO
153	EUCTR2009-016840-38	A Randomized, Open-label, Phase 3 Study of Carfilzomib vs Best Supportive Care in Subjects with Relapsed and Refractory Multiple Myeloma	Onyx Therapeutics, Inc.	2010-04	2015-11	Completed	67	Yes	84	Carfilzomib	Best supportive care	Phase 3	Randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
154	EUCTR2009-017930-35	Phase 3, prospective, multicenter, randomized, double-blind, placebo-controlled, 2-parallel-group study to compare the efficacy and safety of masitinib 6 mg / kg / day in combination with bortezomib and dexamethasone, with placebo in combination with bortezomib and dexamethasone in the treatment of patients with recurrent multiple myeloma who have received prior therapy.	AB Science	2011-07	2017-02	Completed	67	NA	250	Masitinib + bortezomib + dexamethasone,	Placebo + bortezomib + dexamethasone	Phase 3	Randomized	EORTC QLQ-C30	WHO
155	EUCTR2010-023772-71	An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination with a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly-Diagnosed Multiple Myeloma Requiring Systemic Treatment.	Millennium Pharmaceuticals, Inc	2011-07	2016-12	Completed	65	Yes	163	MLN9708 + melphalan + prednisone	NA	Phase 1/ Phase 2	Non- randomized	NA	WHO
156	EUCTR2011-004783-30	An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells	Sanofi aventis recherche et développement	2014-08	2016-09	Completed	25	Yes	20	G-CSF Alone (tumor cell mobilization)	G-CSF + plerixafor	Phase 2	Randomized	NA	WHO
157	EUCTR2011-004795-11	Study to evaluate optimized retreatment and prolonged therapy with bortezomib	Janssen-Cilag International N.V.	2013-03	2016-02	Completed	35	Yes	240	Bortezomib	Standard of care	Phase 3	Randomized	Eq-5d (Primary), QoL (Primary), QoL (Secondary)	WHO
158	EUCTR2014-001052-39	This study is designed to assess the efficacy and safety of filanesib + carfilzomib versus single-agent carfilzomib in patients with multiple myeloma who have received at least 2 prior lines of therapy.	Array BioPharma Inc.	2014-02	2015-08	Completed	18	NA	552	Filanesib + carfilzomib	Carfilzomib	Phase 3	Randomized	NA	WHO
159	EUCTR2014-002749-23	Ixazomib in combination to thalidomide - dexamethasone for patients with relapsed and/or refractory multiple myeloma	AGMT gGmbH	2016-03	2019-03	Completed	36	Yes	80	Ixazomib + thalidomide + dexamethasone	NA	Phase 2	Non-randomized	QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
160	EUCTR2015-002901-12	Study of Lenalidomide and Dexamethasone with or without Pembrolizumab in newly diagnosed and treatment-naïve Multiple Myeloma.7	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	2016-04	2020-07	Completed	51	NA	640	Pembrolizumab + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 3	Randomized	NA	WHO

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
161	EUCTR2015-002993-19	Early Access Treatment with Daratumumab for (Relapsed or Refractory) Multiple Myeloma	Janssen-Cilag International N.V.	2016-02	2018-08	Completed	30	Yes	2000	Daratumumab	NA	Early Access	Non-randomized	NA	WHO
162	EUCTR2015-004411-20	A study evaluating venetoclax in Multiple Myeloma subjects, who are receiving bortezomib and dexamethasone as standard therapy.	AbbVie Deutschland GmbH & Co. KG	2016-07	NA	Ongoing	NA	NA	280	Venetoclax + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary)	WHO
163	EUCTR2015-004831-11	A study to decide what is the right dose of durvalumab to take in combination with lenalidomide with or without dexamethasone to treat a cancer of the bone marrow that is newly diagnosed.	Celgene International II Sàrl	2016-01	NA	Suspended	NA	NA	138	Durvalumab + lenalidomide + dexamethasone	Durvalumab + lenalidomide,	Phase 1/ Phase 2	Non-randomized	NA	WHO
164	EUCTR2016-003097-41	Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients	Sanofi-aventis recherche & développement	2017-04	2018-11	Completed	19	Yes	300	Isatuximab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
165	EUCTR2017-003838-88	Phase 3 Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma	AbbVie Deutschland GmbH & Co. KG	2018-04	NA	Ongoing	NA	NA	244	Venetoclax + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
166	EUCTR2018-002879-17	Safety and Efficacy of AMG 420 in Subjects with With Relapsed and/or Refractory Multiple Myeloma	Amgen Inc	2019-02	NA	Completed	NA	No	120	AMG420	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
167	NCT01665014	Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma	Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice	2012-08	2016-08	Unknown	48	No	50	Double autologous hematopoietic stem cell transplantation + sequential use of total marrow irradiation + high-dose melphalan	NA	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
161	EUCTR2015-002993-19	Early Access Treatment with Daratumumab for (Relapsed or Refractory) Multiple Myeloma	Janssen-Cilag International N.V.	2016-02	2018-08	Completed	30	Yes	2000	Daratumumab	NA	Early Access	Non-randomized	NA	WHO
162	EUCTR2015-004411-20	A study evaluating venetoclax in Multiple Myeloma subjects, who are receiving bortezomib and dexamethasone as standard therapy.	AbbVie Deutschland GmbH & Co. KG	2016-07	NA	Ongoing	NA	NA	280	Venetoclax + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary)	WHO
163	EUCTR2015-004831-11	A study to decide what is the right dose of durvalumab to take in combination with lenalidomide with or without dexamethasone to treat a cancer of the bone marrow that is newly diagnosed.	Celgene International II Sàrl	2016-01	NA	Suspended	NA	NA	138	Durvalumab + lenalidomide + dexamethasone	Durvalumab + lenalidomide,	Phase 1/ Phase 2	Non-randomized	NA	WHO
164	EUCTR2016-003097-41	Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients	Sanofi-aventis recherche & développement	2017-04	2018-11	Completed	19	Yes	300	Isatuximab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
165	EUCTR2017-003838-88	Phase 3 Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14)-Positive Relapsed or Refractory Multiple Myeloma	AbbVie Deutschland GmbH & Co. KG	2018-04	NA	Ongoing	NA	NA	244	Venetoclax + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30	WHO
166	EUCTR2018-002879-17	Safety and Efficacy of AMG 420 in Subjects with With Relapsed and/or Refractory Multiple Myeloma	Amgen Inc	2019-02	NA	Completed	NA	No	120	AMG420	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
167	NCT01665014	Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma	Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice	2012-08	2016-08	Unknown	48	No	50	Double autologous hematopoietic stem cell transplantation + sequential use of total marrow irradiation + high-dose melphalan	NA	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
168	CTRI/2017/11/010561	Study of Selinexor, Bortezomib, ANDDexamethasone Versus Bortezomib andDexamethasone In Patients With Relapsed OrRefractory Multiple Myeloma	Karyopharm Therapeutics Inc	2018-02	NA	Unknown	NA	NA	364	Selinexor + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	NA	WHO
169	NCT00526734	A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM)	Erasme University Hospital	2006-02	NA	Unknown	NA	No	100	Pegfilgrastim	Filgrastim	Phase 2	Randomized	NA	NCT
170	PER-040	A Phase 1/2 Dose Escalation Safety, Pharmacokinetic And Efficacy Study Of Multiple Intravenous Administrations Of A Humanized Monoclonal Antibody (SAR650984) Against CD38 In Patients With Selected Cd38+ Hematological Malignancies	Sanofi Aventis Recherche & Development,	2017-03	2018-06	Completed	15	Yes	6	Isatuximab	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
171	NCT01712789	A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma	Celgene	2012-11	2019-12	Completed	85	NA	720	Pomalidomide + low dose dexamethasone	NA	Phase 3	Non-randomized	NA	NCT
172	NCT02136134	Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma	Janssen Research & Development, LLC	2014-08	2016-01	Completed	17	Yes	480	Daratumumab + bortezomib + dexamethasone (DVd)	Bortezomib + dexamethasone (Vd)	Phase 3	Randomized	NA	NCT
173	NCT02270307	Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis	National Research Center for Hematology, Russia	2014-01	2016-01	Completed	24	Yes	40	Cyclophosphamide	NA	Phase 2/ Phase 3	Non-randomized	NA	NCT
174	NCT02654132	An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)	Bristol-Myers Squibb	2016-03	2018-01	Completed	22	Yes	121	Elotuzumab + pomalidomide + dexamethasone	Pomalidomide + dexamethasone	Phase 2	Randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
175	NCT02659293	Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma	University of Chicago	2016-04	2022-05	Ongoing	73	No	180	Carfilzomib + lenalidomide + dexamethasone	Lenalidomide	Phase 3	Randomized	NA	NCT
176	NCT02899052	A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma	AbbVie	2017-01	2025-08	Ongoing	103	No	120	Venetoclax + carfilzomib + dexamethasone	NA	Phase 2	Non-randomized	NA	NCT
177	NCT03151811	A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide	Oncopeptides AB	2017-06	2022-07	Ongoing	61	No	450	Melflufen+ dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
178	NCT03292263	Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma	St. Petersburg State Pavlov Medical University	2017-04	2021-12	Ongoing	56	No	30	Nivolumab	NA	Phase 1/ Phase 2	Non-randomized	NA	NCT
179	NCT03376672	A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients	Helsinki University Central Hospital	2018-05	2027-12	Ongoing	115	No	120	Ixazomib + lenalidomide + dexamethasone (IRd)	Ixazomib and Lenalidomide and MRD after Lenalidomide	Phase 2	Non-randomized	NA	NCT
180	NCT03481556	An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma	Oncopeptides AB	2018-04	2021-12	Ongoing	44	No	80	Melflufen + dexamethasone + bortezomib	Melflufen + dexamethasone + daratumumab	Phase 1/ Phase 2	Non-randomized	NA	NCT
181	NCT03539744	A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma	AbbVie	2018-10	2024-03	Ongoing	65	No	244	Venetoclax + dexamethasone	Pomalidomide + dexamethasone	Phase 3	Randomized	NA	NCT
182	NCT03639610	A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function	Oncopeptides AB	2018-08	2021-12	Ongoing	40	No	25	Melphalan + melflufen +dexamethasone	NA	Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
183	NCT03673826	Carfilzomib, Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma: A Randomized Phase II Study.	Stichting Hemato-Oncologie voor Volwassenen Nederland	2018-11	2025-10	Ongoing	83	No	120	Carfilzomib + lenalidomide + dexamethasone	Lenalidomide + dexamethasone	Phase 2	Randomized	NA	NCT
184	NCT03697655	Pre-emptive Daratumumab Therapy of Minimal Residual Disease Reappearance or Biochemical Relapse in Multiple Myeloma (PREDATOR)	Polish Myeloma Consortium	2018-12	2024-07	Ongoing	67	No	274	Daratumumab	Observation	Phase 2	Randomized	NA	NCT
185	NCT03859427	A Randomized, Open-label, Phase 3 Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)	Amgen	2019-05	2022-05	Ongoing	36	No	460	Carfilzomib + lenalidomide + dexamethasone once weekly	Carfilzomib + lenalidomide + dexamethasone twice weekly	Phase 3	Randomized	NA	NCT
186	NCT03871829	A Phase 2 Study of Daratumumab Subcutaneous (Dara-SC) Administration in Combination With Carfilzomib and Dexamethasone (DKd) Compared With Carfilzomib and Dexamethasone (Kd) in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) to Evaluate Daratumumab Retreatment	Janssen Research & Development, LLC	2019-05	2024-05	Ongoing	60	No	230	Daratumumab subcutaneous + carfilzomib + dexamethasone (DKd)	Carfilzomib + examethasone (Kd)	Phase 2	Randomized	NA	NCT
187	NCT03896737	A Multicenter, Open Label, Randomized Phase II Study Comparing Daratumumab Combined With Bortezomib-Cyclophosphamide-dexamethasone (Dara-VCd) Versus the Association of Bortezomib-Thalidomide-dexamethasone (VTd) as Pre Transplant Induction and Post Transplant Consolidation, Both Followed by a Maintenance Phase With Ixazomib Alone or in Combination With Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation	European Myeloma Network	2019-04	2025-02	Ongoing	70	No	400	Daratumumab + bortezomib + cyclophosphamide + dexamethasone (Dara-VCd)	Bortezomib + thalidomide + dexamethasone (VTd)	Phase 2	Randomized	NA	NCT
188	NCT03989414	A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)	Celgene	2019-09	2025-01	Ongoing	64	No	215	CC-92480 + bortezomib + dexamethasone	CC-92480 + daratumumab + dexamethasone or. CC-92480 + carfilzomib + dexamethasone	Phase 1/ Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
189	NCT04035226	A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment	Janssen-Cilag Ltd.	2019-08	2022-10	Ongoing	38	No	230	Standard of Care	NA	NA	Non-randomized	NA	NCT
190	NCT04181827	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma	Janssen Research & Development, LLC	2020-06	2026-04	Ongoing	70	No	400	JNJ-68284528 (CAR-T)	Pomalidomide + bortezomib + dexamethasone (PVd) or daratumumab + pomalidomide + dexamethasone (DPd)	Phase 3	Randomized	NA	NCT
191	NCT04242121	The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood	St. Petersburg State Pavlov Medical University	2020-01	2024-01	Ongoing	48	No	100	Risk Stratification based on fluorescence flow cytometry	NA	NA	Non-randomized	NA	NCT
192	NCT04246047	DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma	GlaxoSmith-Kline	2020-05	2026-08	Ongoing	75	No	478	Belantamab mafodotin + bortezomib + dexamethasone (B-Vd)	Daratumumab + bortezomib + dexamethasone (D-Vd)	Phase 3	Randomized	NA	NCT
193	NCT02755597	A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors	AbbVie	2016-07	2022-02	Suspended	67	No	298	Venetoclax + bortezomib + dexamethasone	Placebo + bortezomib + dexamethasone	Phase 3	Randomized	NA	NCT
194	NCT00499239	Multi-center, Open-label, Dose-escalating Phase I/II Trial of GS-9219 Administered Once Every Three Weeks Intravenously to Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma or Multiple Myeloma	Gilead Sciences	2007-07	2010-10	Terminated	39	No	32	GS-9219	NA	Phase 1/ Phase 2	Non-randomized	NA	NCT

APPENDICES

Table 22: Published results of the 201 trials which enrolled CEE patients (November 2020)

N°	Trial ID	Official Title	Study Lead	Start Date	Completion Date	Study Status	Study Duration (months)	Results Available (Nov. 2020)	Patients Enrolled	Investigational product	Comparator Product	Phase	Trial Design	QoL Collected	Database of Origin
195	NCT01002248	A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients	AEterna Zentaris	2009-12	2013-03	Terminated	39	No	135	Perifosine + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	NA	NCT
196	NCT01266811	A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma	Centocor, Inc.	2011-07	2014-12	Withdrawn	41	No	0	Siltuximab + VELCADE + dexamethasone	Placebo + bortezomib + dexamethasone	Phase 3	Randomized	NA	NCT
197	EUCTR2018-000813-19	Safety and antitumor activity of autologous CD44v6 CAR T-cells in acute myeloid leukemia and multiple myeloma expressing CD44v6.	MolMed S.p.A.	2019-09	NA	Ongoing	NA	No	68	MLM-CAR44.1	NA	Phase 1/ Phase 2	Non-randomized	NA	WHO
198	NCT04483739	Phase III Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) Versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL	European Myeloma Network	2020-09	2025-07	Ongoing	58	No	300	Isatuximab + carfilzomib + lenalidomide + dexamethasone (Isa-KRd)	Carfilzomib + lenalidomide + dexamethasone (KRd)	Phase 3	Randomized	NA	NCT
199	NCT04492371	COVID-19 Infection In Multiple Myeloma Patients: An European Observational Study	European Myeloma Network	2020-07	2021-08	Ongoing	13	No	500	Covid management	NA	Observation	Non-randomized	NA	NCT
200	EUCTR2008-006421-13	Multicenter Phase II Study:Bendamustine plus Bortezomib plus Dexamethasone in the treatment of stage II/III relapsed or refractory multiple myeloma	Wilhelminen Krebsforschung GmbH	2008-11	2012-12	Completed	49	Yes	79	Bendamustine + bortezomib + dexamethasone	NA	Phase 2	Non-randomized	NA	WHO
201	EUCTR2010-018893-19	A Phase III Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib	Aeterna Zentaris GmbH	2011-08	NA	Terminated	NA	No	135	Perifosine + bortezomib + dexamethasone	Bortezomib + dexamethasone	Phase 3	Randomized	NA	WHO

APPENDICES

6.2.3. ONLY 0.6% OF PATIENTS RECRUITED IN ALL MYELOMA TRIALS (N=3,229) ARE FROM CEE COUNTRIES: CALCULATION DETAILS

- Overall enrolment in the known registered 3,229 myeloma trials was approximately 2,770,000 patients
- Out of 3,229 myeloma trials, only 201 (6%) enrolled patients from CEE countries
- Eleven out of 201 trials were either terminated withdrawn or suspended and thus excluded from the estimate
- It was known that a total of 4,822 patients from CEE countries were enrolled across 46 trials out those 201 trials
- It was unknown how many CEE patients were enrolled in the remaining 144 trials because they were either still ongoing or have not reported per country enrolment
- The total enrolment in these 144 trials is 59,946 patients
- If we extrapolate from the known level of enrolment (and there is no evidence to assume otherwise), that CEE enrolment rate is 24.5%, we can estimate that about 12,971 CEE patients were enrolled into those 144 trials
- Thus, putting together the known and estimated number of the CEE patients in the myeloma clinical trials (12,971 and 4,822), the number of CEE patients is unlikely to exceed 18,000
- This is 0.6% of the total 2,770,000 patients enrolled in registered myeloma trials

APPENDICES

6.2.4. QUALITY OF LIFE DATA IN CEE MYELOMA TRIALS

Table 23: Quality of life data in CEE myeloma trials

Trial ID	Type of QoL Data collected
NCT00656305	Brief Pain Inventory (BPI)
EUCTR2004-001989-41	EORTC QLQ-C30
EUCTR2007-004138-17	QoL (Primary)
EUCTR2010-020347-12	EORTC QLQ-C30, QLQ MY20
EUCTR2013-003265-34	QLQ-MY20, EORTC QLQ-C30
EUCTR2013-003789-15	QoL (Primary), QoL (Secondary)
EUCTR2014-000255-85	Eq-5d (Primary), Patient reported outcome(s) (Primary), EORTC QLQ-C30
EUCTR2014-002272-88	Patient reported outcome(s) (Primary)
EUCTR2015-001564-19	HRQoL (Primary), HRQoL (Secondary), QoL (Primary), EORTC QLQ-C30
EUCTR2016-001205-16	Eq-5d (Secondary), HRQoL (Primary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2016-003957-14	Eq-5d (Secondary), EORTC QLQ-C30
EUCTR2016-004742-28	Eq-5d (Primary), Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2017-001618-27	Eq-5d (Secondary), HRQoL (Primary), QoL (Primary), EORTC QLQ-C30
EUCTR2017-002611-34	Eq-5d (Primary), Eq-5d (Secondary), QoL (Primary), EORTC QLQ-C30
EUCTR2017-003253-41	QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2018-002089-37	QoL data and health economics data collected as primary outcomes
EUCTR2018-004252-38	HRQoL (Primary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2019-002161-36	Eq-5d (Secondary), Patient reported outcome(s) (Primary), EORTC QLQ-C30,
EUCTR2019-003047-30	HRQoL (Primary), HRQoL (Secondary), EORTC QLQ-C30
EUCTR2019-003139-47	Eq-5d (Secondary), EORTC QLQ-C30
EUCTR2019-004844-32	Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30
NCT01241396	QoL data and health economics data collected as secondary outcomes
EUCTR2004-001426-24	QoL data and health economics data collected as primary outcomes
EUCTR2005-002756-18	QoL data and health economics data collected as primary outcomes
EUCTR2005-004937-16	QoL data and health economics data collected as primary outcomes
EUCTR2009-017930-35	EORTC QLQ-C30
EUCTR2011-004795-11	Eq-5d (Primary), QoL (Primary), QoL (Secondary)
EUCTR2014-002749-23	QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2015-004411-20	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary)
EUCTR2016-003097-41	Eq-5d (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30
EUCTR2017-003838-88	Patient reported outcome(s) (Primary), Patient reported outcome(s) (Secondary), QoL (Primary), QoL (Secondary), EORTC QLQ-C30

CONTACT US

Myeloma Patients Europe AISBL
Avenue Louise 143/4
1050 Brussels - Belgium

info@mpeurope.org

www.mpeurope.org

@mpeurope

@MyelomaEurope

Myeloma Patients Europe

Myeloma Patients Europe